Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.37 |
| ▸ | CDK2 | P24941 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366011 | 0.89 | ERBB2 (0.61) | ERBB2EGFRTDP1PLK4LRRK2 | |
| SCHEMBL5362776 | 0.87 | ERBB2 (0.67) | ERBB2EGFRTSHRTDP1PLK4 | |
| SCHEMBL7137076 | 0.86 | ERBB2 (0.46) | ERBB2EGFRALDH1A1TSHRTDP1 | |
| SCHEMBL5357756 | 0.85 | ERBB2 (0.56) | ERBB2EGFRTSHRTDP1PLK4 | |
| SCHEMBL5376941 | 0.85 | ERBB2 (0.61) | ERBB2EGFRTDP1PLK4LRRK2 | |
| SCHEMBL5366009 | 0.79 | ERBB2 (0.62) | ERBB2EGFRALDH1A1TDP1PLK4 | |
| SCHEMBL5369680 | 0.79 | ERBB2 (0.56) | ERBB2EGFRTSHRTDP1PLK4 | |
| SCHEMBL5364049 | 0.79 | ERBB2 (0.59) | ERBB2EGFRTSHRTDP1PLK4 | |
| SCHEMBL5367617 | 0.78 | ERBB2 (0.53) | ERBB2EGFRTSHRTDP1PLK4 | |
| SCHEMBL5358747 | 0.78 | PLK4 (0.60) | ERBB2EGFRALDH1A1TDP1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | ERBB2 19/4885EGFR 286/4885ALDH1A1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.